Brokerages forecast that Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) will post earnings per share of ($0.14) for the current quarter, according to Zacks. Zero analysts have issued estimates for Aptose Biosciences’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.15). Aptose Biosciences posted earnings per share of ($0.30) during the same quarter last year, which indicates a positive year over year growth rate of 53.3%. The company is expected to report its next earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Aptose Biosciences will report full year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.70) to ($0.54). For the next fiscal year, analysts expect that the firm will post earnings of ($0.74) per share, with EPS estimates ranging from ($0.80) to ($0.64). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that follow Aptose Biosciences.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.03.

A number of research firms recently weighed in on APTO. Roth Capital reiterated a “buy” rating on shares of Aptose Biosciences in a research report on Thursday, May 23rd. Zacks Investment Research upgraded Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a research report on Friday, March 15th. HC Wainwright set a $9.00 price target on Aptose Biosciences and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Finally, Royal Bank of Canada began coverage on Aptose Biosciences in a research report on Friday, March 1st. They issued an “outperform” rating and a $6.00 price target for the company. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $5.75.

In related news, Director Erich Platzer sold 20,000 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total value of $43,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders purchased a total of 27,500 shares of company stock valued at $51,300 in the last quarter. 7.34% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in Aptose Biosciences in the first quarter worth $35,000. Patriot Financial Group Insurance Agency LLC increased its position in Aptose Biosciences by 37.3% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 78,829 shares of the biotechnology company’s stock worth $158,000 after buying an additional 21,400 shares during the period. Boston Advisors LLC acquired a new stake in Aptose Biosciences in the first quarter worth $36,000. Virtu Financial LLC acquired a new stake in Aptose Biosciences in the first quarter worth $198,000. Finally, Geode Capital Management LLC acquired a new stake in Aptose Biosciences in the fourth quarter worth $33,000. Institutional investors and hedge funds own 7.53% of the company’s stock.

Shares of NASDAQ:APTO traded up $0.14 during midday trading on Wednesday, reaching $2.15. The company had a trading volume of 654,522 shares, compared to its average volume of 290,342. The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.09. Aptose Biosciences has a 1-year low of $1.57 and a 1-year high of $4.55. The firm has a market capitalization of $87.09 million, a price-to-earnings ratio of -2.50 and a beta of 1.43.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Recommended Story: What is systematic risk?

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with's FREE daily email newsletter.